ICU Medical, Inc. (ICUI) Stock Price & How to Invest

ICU Medical makes the plumbing of hospital drug delivery. Its Consumables segment sells IV sets, needle-free connectors (the CLAVE family it has built its reputation on), oncology and vascular access products, and tracheostomy devices. Infusion Systems sells the large volume, syringe and ambulatory pumps that push those fluids, including the Plum Duo and Plum Solo platforms plus the LifeShield safety software layer and the CADD and Medfusion pumps inherited from Smiths Medical. Vital Care is the catch-all for temperature management, respiratory, cardiac monitoring and the IV solutions business, most of which now sits inside Otsuka ICU Medical LLC, the joint venture formed in May 2025 when ICU sold 60% of IV Solutions to Otsuka Pharmaceutical Factory America and kept a 40% stake. Revenue for full year 2025 was about $2.23 billion, down roughly 6% on a reported basis almost entirely because of that deconsolidation, with Consumables at about $1.11 billion, Infusion Systems at about $684 million and Vital Care at about $438 million.

The investment picture is a repair job. ICU Medical paid about $2.35 billion in cash and stock for Smiths Medical in January 2022, roughly doubling its size and, by management's own account, taking on far more integration work, quality remediation and manufacturing complexity than it expected. The years since brought recalls, an FDA warning letter in April 2025 covering the Medfusion Model 4000 and CADD Solis VIP pumps, compressed margins and a stretch of GAAP losses. What has changed recently is the direction of travel. Second quarter 2026 revenue was about $552 million, up about 6% organically, with Infusion Systems up about 12% and Consumables up about 5%, offsetting a roughly 4% organic decline in Vital Care. Adjusted EBITDA reached about $110 million and adjusted EPS about $2.37, and management raised full year adjusted EPS guidance to a range of about $8.60 to $9.00 from about $7.75 to $8.45. Net debt sat near $942 million and net leverage near 2.3 times, with a stated target of about 2.0 times by year end. The shares trade near $187, which puts them around 21 times the midpoint of that adjusted EPS guide, so the market is paying for a recovery that is underway but not finished.

Regulatory and quality exposure is the most specific risk. The FDA issued a warning letter in April 2025 stating that ICU Medical made changes to the Medfusion Model 4000 syringe pump and the CADD Solis VIP ambulatory pump without the required premarket submissions, and that letter followed a run of recalls dating back to the Smiths integration, so remediation costs and any further enforcement action remain open items. Several plaintiff law firms announced securities fraud investigations after that disclosure, and while ICU Medical describes its litigation as ordinary course, headline risk on this front has not gone away. Operationally, tariffs are running at an estimated $30 million to $40 million annually, yen weakness has been a multi-year currency headwind, and hospital capital budgets can defer pump purchases in a downturn. Financially, leverage near 2.3 times leaves less room for a stumble than a debt-free peer would have, and the gap between guided GAAP EPS of roughly $2.89 to $3.29 and adjusted EPS of roughly $8.60 to $9.00 is large enough that how an investor treats amortization and restructuring charges materially changes what the stock looks like.

8 analysts publish price targets on ICUI, averaging $182.50 against a $185.78 price as of August 2026, or -1.8%. The published targets run from $165.00 to $200.00, a narrow spread, and the ratings split 7 buy, 1 hold, 0 sell. Over the last six months there have been 5 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ICUI forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on ICU Medical, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The Infusion Systems replacement cycle. Infusion Systems grew about 12% organically in the second quarter of 2026, driven largely by competitive win installations rather than upgrades within the existing base. The most optimistic published target, $200.00, assumes this works close to its best case.

The case against. Regulatory and quality exposure is the most specific risk. The most pessimistic target, $165.00, is roughly what ICUI is worth if this bites instead.

Read the full bull and bear case on ICUI, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see ICU Medical, Inc.'s investor relations page or your broker.

• Revenue (FY2025): ~$2.23 billion
• Q2 2026 revenue: ~$552 million, ~6% organic growth
• Adjusted EBITDA (FY2026 guide): ~$415 million to ~$435 million
• Adjusted EPS (FY2026 guide): ~$8.60 to ~$9.00
• Market cap: ~$4.7 billion (shares near ~$187)
• Net debt / leverage: ~$942 million, ~2.3x trailing adjusted EBITDA

At roughly $187 per share, ICUI trades near 21 times the midpoint of its guided adjusted EPS and around 13 times enterprise value to guided adjusted EBITDA, which is a discount to large-cap medical device peers and reflects the leverage plus the unfinished integration. The gap between GAAP and adjusted numbers is unusually wide here, with FY2026 GAAP EPS guided to roughly $1.03 to $1.74 originally and raised to roughly $2.89 to $3.29, because acquisition amortization, restructuring and integration costs are excluded from the adjusted figures. ICU Medical pays no dividend and directs its cash toward debt repayment instead.

Other names that sit close to ICUI: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get ICUI exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ICUI sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ICUI fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

ICUI is a mid-cap hospital consumables and infusion business in the middle of a margin and balance sheet repair, so the story hinges on execution rather than on any single product launch.

Whether ICUI is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ICUI a buy or a sell?, and where the stock could go from here in the ICUI stock forecast.

For income investors, whether ICUI pays a dividend and how the payout looks is covered in does ICUI pay a dividend? And to weigh ICUI against a peer, read the full side-by-side comparisons: ICUI vs BAX and ICUI vs TFX.